Robert Marcus

11.1k total citations · 1 hit paper
172 papers, 6.9k citations indexed

About

Robert Marcus is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Robert Marcus has authored 172 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Pathology and Forensic Medicine, 61 papers in Oncology and 51 papers in Genetics. Recurrent topics in Robert Marcus's work include Lymphoma Diagnosis and Treatment (88 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Viral-associated cancers and disorders (38 papers). Robert Marcus is often cited by papers focused on Lymphoma Diagnosis and Treatment (88 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Viral-associated cancers and disorders (38 papers). Robert Marcus collaborates with scholars based in United Kingdom, Germany and Switzerland. Robert Marcus's co-authors include J. Andrew Bradley, Anna L. Taylor, Anton Hagenbeek, Eva Kimby, Wolfgang Hiddemann, M. van Glabbeke, Richard Klasa, Marinus H. J. van Oers, Max Wolf and Michael Herold and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Robert Marcus

171 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

2017 461 citations Robert Marcus, Elizabeth H. Phillips et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Marcus United Kingdom	40	3.5k	3.1k	2.0k	1.1k	933	172	6.9k
Grzegorz S. Nowakowski United States	43	3.3k 0.9×	3.4k 1.1×	1.6k 0.8×	775 0.7×	1.2k 1.3×	346	6.3k
Aaron Polliack Israel	43	2.5k 0.7×	1.8k 0.6×	2.2k 1.1×	1.4k 1.3×	1.9k 2.0×	375	7.7k
Andrew M. Evens United States	49	3.3k 1.0×	3.5k 1.1×	1.2k 0.6×	973 0.9×	1.1k 1.2×	305	7.8k
Ian Magrath United States	53	3.8k 1.1×	5.1k 1.6×	1.4k 0.7×	878 0.8×	1.5k 1.6×	173	9.7k
Jorge J. Castillo United States	52	5.0k 1.4×	3.3k 1.0×	3.8k 1.9×	1.5k 1.4×	1.6k 1.7×	373	8.0k
Antonio Martı́nez Spain	45	2.9k 0.8×	2.8k 0.9×	1.2k 0.6×	423 0.4×	1.4k 1.5×	157	6.7k
Gerard Lozanski United States	43	2.1k 0.6×	1.7k 0.5×	2.0k 1.0×	1.2k 1.1×	1.6k 1.7×	176	6.4k
Olivier Casasnovas France	54	4.9k 1.4×	3.0k 1.0×	1.5k 0.7×	786 0.7×	727 0.8×	272	8.5k
Georg Heß Germany	39	2.1k 0.6×	2.2k 0.7×	1.4k 0.7×	758 0.7×	1.2k 1.3×	192	6.6k
Pierre Biron France	50	4.5k 1.3×	4.7k 1.5×	2.0k 1.0×	1.6k 1.4×	988 1.1×	292	10.6k

Countries citing papers authored by Robert Marcus

Since Specialization

Citations

This map shows the geographic impact of Robert Marcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Marcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Marcus more than expected).

Fields of papers citing papers by Robert Marcus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Marcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Marcus. The network helps show where Robert Marcus may publish in the future.

Co-authorship network of co-authors of Robert Marcus

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Marcus. A scholar is included among the top collaborators of Robert Marcus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Marcus. Robert Marcus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Townsend, William, Wolfgang Hiddemann, Christian Buske, et al.. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. 7(7). e919–e919. 27 indexed citations

Casulo, Carla, Jesse G. Dixon, Fang‐Shu Ou, et al.. (2021). Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances. 5(6). 1737–1745. 3 indexed citations

Klánová, Magdalena, Mikkel Z. Oestergaard, Marek Trněný, et al.. (2019). Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clinical Cancer Research. 25(15). 4634–4643. 54 indexed citations

Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology. 36(23). 2395–2404. 144 indexed citations

Pott, Christiane, Eva Hoster, Michael Unterhalt, et al.. (2018). Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. Blood. 132(Supplement 1). 396–396. 20 indexed citations

Townsend, William, Christian Buske, Guillaume Cartron, et al.. (2018). Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study. Blood. 132(Supplement 1). 1597–1597. 11 indexed citations

Launonen, Aino, et al.. (2017). Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study. Blood. 130. 1490–1490. 12 indexed citations

Coutinho, Rita, Alessia Dalla Pria, Katharine Bailey, et al.. (2013). HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS. 28(5). 689–697. 45 indexed citations

Oers, Marinus H. J. van, Evelyn Tönnissen, M. van Glabbeke, et al.. (2010). BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study. Journal of Clinical Oncology. 28(13). 2246–2252. 34 indexed citations

10.

Camilleri, Duncan, et al.. (2009). Intermediate dose gemcitabine–cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting—a new standard of care in relapsed or refractory Hodgkin lymphoma?. Annals of Hematology. 88(11). 1107–1112. 4 indexed citations

11.

Marcus, Robert. (2007). Should you tell patients about beneficial treatments that they cannot have? Yes. BMJ. 334(7598). 826–826. 9 indexed citations

12.

Taylor, Anna L., Robert Marcus, & J. Andrew Bradley. (2005). Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Critical Reviews in Oncology/Hematology. 56(1). 155–167. 283 indexed citations

13.

Nadelman, Robert B., John Nowakowski, Durland Fish, et al.. (2001). Prophylaxis with Single-Dose Doxycycline for the Prevention of Lyme Disease after anIxodes scapularisTick Bite. New England Journal of Medicine. 345(2). 79–84. 288 indexed citations

14.

Bloor, Adrian, et al.. (1998). Two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodgkin‘s lymphoma. Clinical & Laboratory Haematology. 20(2). 119–121. 4 indexed citations

15.

Hoffman, Andrew R., S. Lieberman, G. E. Butterfield, et al.. (1997). Functional consequences of the somatopause and its treatment. Endocrine. 7(1). 73–76. 20 indexed citations

16.

Bird, Jennifer M., Diana Samson, Robert Marcus, et al.. (1994). Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. British Journal of Haematology. 88(1). 110–116. 41 indexed citations

17.

Lim, Seah H., G Hale, Robert Marcus, Herman Waldmann, & Trevor Baglin. (1993). CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP). British Journal of Haematology. 84. 56–56. 2 indexed citations

18.

Lim, S. H., et al.. (1992). High‐dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease. European Journal Of Haematology. 48(2). 110–114. 4 indexed citations

19.

Marcus, Robert, et al.. (1985). Young Red Cell Preparation – A Comparison of Available Methods. Acta Haematologica. 73(1). 22–25. 2 indexed citations

20.

Marcus, Robert. (1978). Parabolic Itô equations with monotone nonlinearities. Journal of Functional Analysis. 29(3). 275–286. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact